ALK and neoplasm: Time-dependent AUCs for 3-year PFS and 4-year OS prognostic were 0.79 and 0.78, respectively.<h4>Conclusion</h4>Our study established that brain metastasis status, tumor characteristics, and systemic inflammatory markers significantly impact clinical outcomes in ALK-positive NSCLC patients undergoing TKI therapy.